Inactive Instrument

Analyst Reco. GENB AS Other OTC

Equities

US3723032062

Real-time Estimate Cboe BZX Other stock markets 17:37:29 21/05/2024 BST			5-day change	1st Jan Change
29.24 ^USD	+61.16%		+0.50%	+10.11%

05-15	Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation'	MT
05-15	Bolt Biotherapeutics Stops Development of Trastuzumab Imbotolimod, Cuts Workforce by 50%	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

GENMAB : A good start to 2024; guidance unchanged	05-03
GENMAB : Genmab is available at a bargain price	03-04
BMO Capital Upgrades Genmab to Outperform From Market Perform, Adjusts Price Target to $48 From $46	02-23	MT
RBC Cuts Price Target on Genmab to DKK2,400 From DKK2,500, Keeps Sector Perform Rating	02-21	MT
GENMAB : A profitability miss but the market welcomed the better-than-expected sales guidance + share buybacks	02-15
HC Wainwright Raises Price Target on Genmab to $50 From $49, Maintains Buy Rating	01-29	MT
Morgan Stanley Adjusts Price Target on Genmab to $32 From $33, Maintains Underweight Rating	11-09	MT
HC Wainwright Adjusts Price Target on Genmab to $49 From $51, Maintains Buy Rating	11-08	MT
GENMAB : Better-than-expected Q3; lower-end of sales guidance upgraded	11-08
GENMAB : Factoring in some caution	31/10/23
BTIG Raises Price Target on Genmab to $46 From $44, Maintains Buy Rating	13/10/23	MT
GENMAB : Incorporating R&D priorities; attractiveness remains intact	25/08/23
BTIG Starts Genmab at Buy With $44 Price Target	24/08/23	MT
GENMAB : A good Q2 + improved sales guidance	04/08/23
AbbVie, Genmab Say Phase 1/2 Trial of Epcoritamab in Follicular Lymphoma Patients Showed 82% of Overall Response Rate	28/06/23	MT
Genmab Says Epcoritamab Drug Combination Shows 98% Overall Response Rate in Phase 1/2 Trial in Follicular Lymphoma	09/06/23	MT
HC Wainwright Adjusts Price Target on Genmab to $51 From $47, Keeps Buy Rating	22/05/23	MT
HC Wainwright Adjusts Price Target on Genmab to $47 From $46, Maintains Buy Rating	16/05/23	MT
GENMAB : Mixed Q1; attractiveness remains intact, despite profitability miss	11/05/23
GENMAB : Promising 2022; even the softer 2023 guidance isn’t a worry	20/03/23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

GENMAB : A good start to 2024; guidance unchanged

May 03, 2024 at 06:08 pm